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ABSTRACT
Objectives: Despite the growing number of pharmacoeco-
nomic (PE)/health economic (HE) studies, very little is
known about their use by decision makers. The objectives
of the Task Force were to ensure that the good research
practices of PE/HE studies pay attention to the needs of
health-care decision makers and to develop a “toolbox”
for the health-care decision maker wanting to interpret
and use PE/HE studies.
Methods: The membership of the Task Force consisted of
individuals involved in making decisions about the avail-
ability or use of medicines and researchers into the use of
economic evaluations. The group communicated by E-
mail and face-to-face meetings. A literature review of
decision makers’ attitudes toward PE/HE studies and
published economic evaluation guidelines was under-
taken. In addition, a focus group discussion was held with
opinion leaders in managed care pharmacy.
Results: The literature review identiﬁed 16 surveys of
decision makers’ attitudes toward PE/HE studies and 15
published guidelines that outlined reporting requirements
for economic evaluations. These were reviewed and clas-
siﬁed. Based on the published literature and comments
from decision makers, seven additional reporting require-
ments for studies were speciﬁed.
Conclusions: While the Task Force’s additional reporting
requirements may be helpful to decision makers, they
raise a number of issues. These include the feasibility of
meeting the additional requirements, whether decision
makers should receive more education in economic eval-
uation, and whether there should be more study of health-
care decision-making procedures themselves.
Keywords: cost-effectiveness analysis, decision making,
guidelines, implementation.
Introduction
Despite the growing number of pharmacoeconomic/
health economic (PE/HE) studies and the methodo-
logical developments in recent years, very little is
known about the attitudes of decision makers
toward such studies. That is, are studies used and, if
so, do they have any impact on decision making?
Although PE/HE studies can be undertaken for
academic interest, their main purpose is to help
those making decisions about the allocation of
health-care resources. Therefore, the objectives of
the ISPOR Task Force on the use of PE/HE in
health-care decision making were to ensure that the
good research practices of PE/HE studies pay atten-
tion to the needs of health-care decision makers and
to develop a “toolbox” for the health-care decision
maker wanting to interpret and use PE/HE studies.
This report is organized in the following manner:
First, the contexts for health-care decision making
and the uses of PE/HE studies are discussed. Second,
the Task Force’s methods of working are outlined.
Third, the current literature on decision makers’
attitudes toward PE/HE studies is reviewed. Fourth,
elements of good practice in the reporting of PE/HE
studies are speciﬁed. Finally, several issues for fur-
ther research are outlined.
Contexts for Decision Making and the Uses of 
PE/HE Studies
There are several contexts for health-care decision
making, which may vary from place to place. First,
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at the central level, decisions are made about poli-
cies and programs for the populations of particular
countries or regions. In some jurisdictions these
include centralized procedures for the pricing and
reimbursement of pharmaceuticals (e.g., Australia,
Ontario). In a wider range of jurisdictions there are
national programs for prevention of disease, includ-
ing screening and immunization.
Second, many policy decisions are made at the
local level, namely the health plan, hospital, or
practice. These may include the adoption of treat-
ment guidelines or the inclusion of drugs on the
local or regional formulary of that organization. In
some countries, such as the United States, the
majority of health-care resource allocation deci-
sions are made at the local level.
Finally, health-care resource allocation decisions
are made in all health-care systems at the patient
level. However, in general the main application and
relevance of PE/HE studies is at the central and local
levels, although these decisions undoubtedly condi-
tion the treatment decisions taken by doctors on
behalf of their patients. For example, if a given drug
is not on the local formulary, or is at the third tier
attracting high patient copay, physicians are less
likely to recommend it for their patients if they are
aware of the situation.
Whereas the same elements of good practice
apply to PE/HE studies irrespective of the level of
decision making they seek to inform, there are crit-
ical differences between the central and local levels
that bear on the work of this Task Force. First, at
the central level, expertise is generally available to
evaluate the methodological quality of the studies.
This may not always be the case at the local level.
Second, at the central level there is usually a pre-
scribed process for presenting data and a set of
methodological guidelines that need to be followed.
Again, this may not always be the case at the local
level, although the Academy of Managed Care
Pharmacy (AMCP) format is one attempt to intro-
duce such a process [1].
The main implication of these differences is
that, at the local level, there is much more concern
over whether analyses can be trusted and whether
there are potential biases in research sponsored by
manufacturers. By contrast, at the central level, a
company submission is, by deﬁnition, advocacy
for the product and there is usually sufﬁcient
expertise available to undertake a detailed critical
appraisal.
This suggests that, while elements of good prac-
tice in the conduct and reporting of PE/HE studies
are relevant in all decision-making contexts, deci-
sion makers’ needs for assistance in interpreting
studies are greater at the local level.
Methods of Working
The membership of the Task Force Core Group was
drawn from two constituencies: 1) those involved in
making decisions about the availability or use of
medicines at the central or local level, and 2) those
who had previously undertaken research into the
use of economic evaluations. The Core Group was
supported by a broader group of ISPOR members
(the Reference Group) who offered feedback on the
Task Force’s suggestions. Finally, the Task Force
had access to a researcher, who undertook the liter-
ature review of decision makers’ attitudes toward
PE/HE studies and the classiﬁcation of existing
reporting guidelines.
The Core Group communicated mainly by E-
mail but in addition met face-to-face at three con-
secutive ISPOR meetings in May 2001, November
2001, and May 2002.
Also, four members of the Core Group attended
the AMCP Educational Meeting in Dallas, Texas, in
October 2001. This provided the opportunity to
organize a focus group discussion with 10 opinion
leaders in managed care pharmacy, the outcome of
which was very inﬂuential in shaping the Task
Force’s recommendations.
The Task Force’s draft report was posted on the
ISPOR website toward the end of November 2001.
A wide range of comments was received, in partic-
ular from the ISPOR Special Interest Group on
Managed Care/Pharmacy Beneﬁt Management.
Where relevant, these comments were taken into
account in drafting the ﬁnal report.
Finally, the recommendations of the Task Force
were presented at the Fourth ISPOR European Con-
gress in Cannes, France, in November 2001 and the
Seventh Annual ISPOR International Meeting in
Washington, DC, in 2002.
Review of Decision Makers’ Attitudes toward 
PE/HE Studies
The literature review was conducted by screening
the references identiﬁed by a recent systematic
review of the use of health technology assessment in
health-care decision making, plus articles identiﬁed
in previous literature reviews undertaken by mem-
bers of the Core Group [2]. The systematic review,
being broad in scope, identiﬁed 1040 references.
However, the vast majority were commentaries or
dealt with aspects of health technology assessment
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other than economic evaluation. A much smaller
number of papers (n = 16) reported empirical
research (i.e., surveys) on decision makers’ attitudes
toward PE/HE studies. These are summarized in
Table 1. The general commentaries were used more
generally to inform the Task Force’s debate about
the uses and limitations of PE/HE information in
health-care decision making.
The main conclusions from the review were as
follows: for a study to be useful in a given decision,
the decision maker needs to be convinced of its reli-
ability and relevance. A reliable study would be one
giving accurate estimates that are free from bias. A
relevant study would be one containing results that
apply to the decision maker’s own setting. (Some
authors use the terms “internal” and “external
validity” to refer to the same concepts.) The main
ﬁndings, in relation to reliability and relevance,
from the various surveys are summarized below.
Issues Relating to Reliability
A major general concern of decision makers is the
lack of transparency in the reporting of PE/HE stud-
ies. This concern applies to all studies, but is prob-
ably greatest in the case of modeling studies, with
which most health-care decision makers are less
familiar. The lack of transparency also partly fuels
decision makers’ concerns about the potential spon-
sorship bias in PE/HE studies.
In addition to the relative lack of transparency in
modeling studies, decision makers are often con-
cerned about the extensive use of assumptions and
the extrapolation of beneﬁts over a time scale not
directly observed in the clinical trials themselves.
For example, in one economic evaluation of choles-
terol-lowering therapy, only 10% of the beneﬁt (in
life extension) was observed during the trial itself
[19]. The remainder came from an extrapolation,
over the lifetime of patients, from events (such as
angina) observed during the trial follow-up period.
Whereas most economists would prefer the use
of extrapolation, especially if this leads to the con-
sideration of a more relevant time horizon or more
relevant outcome, decision makers tend to prefer
the observed to the unobserved. The same is true of
the analysis of practice patterns and treatment
costs, where the estimates from physician expert
panels are usually considered inferior to data from a
clinical trial, patients’ charts, or an administrative
database.
Finally, several of the surveys indicate that deci-
sion makers are less comfortable than economists
with the methods for calculating quality-adjusted
life-years (QALYs) and willingness-to-pay. First,
they ﬁnd the concepts behind these beneﬁt measures
a little difﬁcult to understand. Second, they have
some concerns about the reliability of the estima-
tion methods themselves, and third, in respect of
QALYs, they have a more general concern about the
aggregation of health beneﬁts in a single index.
Therefore, decision makers often prefer to see the
various components of beneﬁt presented in a cost-
consequences analysis.
Issues Relating to Relevance
Probably the main issue relating to relevance is that
typically PE/HE studies do not explore budgetary
impact. Whereas the cost-effectiveness ratio gives
an indication of the value for money from a therapy,
it says nothing about total cost. On the other hand,
the decision maker is often more concerned about
affordability, which obviously depends on the over-
all volume of patients likely to beneﬁt from the ther-
apy and on whose budget the costs are likely to fall.
Therefore, decision makers often prefer to see var-
ious budgetary perspectives explored (along with
the societal perspective), as well as an estimate of
overall budgetary impact.
In the case of managed care in the United States,
this may represent a real challenge, owing to the
diversity of plans. However, it may be possible to
develop a “reference case” for managed care, or to
show budgetary impact, under different assump-
tions, for various time frames (e.g., 2 years, 5 years,
etc.) [20].
A common justiﬁcation for investments in higher
cost therapies is that savings will be made elsewhere
in the health-care system (on other budgets) or in
the future. Even those decision makers not adopting
a “silo” mentality (i.e., concern only for their own
budget) sometimes doubt whether many of the sav-
ings will actually be achieved. For example, this
may be dependent on changes in the behavior of
individual physicians. Of course, in many cases
economists refer to freed resources rather than
ﬁnancial savings. That is, the beneﬁt from a shorter
length of hospital stay is that the vacated bed can be
used in the treatment of another patient. Although
decision makers understand these arguments, it is
often difﬁcult for them to take these on board when
living within a ﬁnancial budget constraint. Indeed,
a hospital or a health plan could get into ﬁnancial
difﬁculties by adopting too many cost-effective
interventions.
One way of bringing together the value-for-
money and budgetary considerations would be to
explore the cost-effectiveness ratios and budgetary
impacts of treating different subgroups of patients
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within the total patient population; subgroups are
often deﬁned by indication, or by various pretreat-
ment risk factors. The current consideration of
these issues in PE/HE studies is, at best, erratic.
However, it is also controversial, because there may
be insufﬁcient patient numbers in clinical studies to
demonstrate differences between subgroups of the
overall patient population at the conventional level
of statistical signiﬁcance.
Finally, some decision makers doubt whether PE/
HE studies undertaken in other locations apply in
their settings. There is a substantial literature on the
transferability of PE/HE studies and economists
have developed methods to adapt study results from
one location to another [21]. However, the individ-
ual decision maker may still require a presentation
of study results that reﬂects the local situation.
Often this can be dealt with by the use of sensitivity
analysis or interactive models.
Recommendations for the Reporting of 
PE/HE Studies
There are now a number of guidelines for the
conduct and reporting of PE/HE studies. Some
originate from decision-making bodies, in those
jurisdictions where there is a formal requirement for
cost-effectiveness evidence. Others originate from
groups of academic researchers or related groups
interested in maintaining methodological standards
in this ﬁeld of research.
Twenty-ﬁve existing guidelines have recently
been reviewed by Hjelmgren et al. [22]. They con-
cluded that, while there were differences among the
published guidelines, there was substantial harmo-
nization of methodological standards. The level of
agreement on methodological aspects was slightly
higher for the formal guidelines than for informal
guidelines or general guidelines on health economic
methods.
Not all the available guidelines for PE/HE studies
specify a standard reporting framework or tem-
plate. Details of 15 that do are given in Fig. 1. It can
be seen that there is a fair amount of agreement
between the different guidelines in terms of report-
ing requirements. In the main they are aimed at
increasing transparency (e.g., state what compara-
tor was used), although sometimes they embody ele-
ments of methodological prescription (e.g., present
the results with costs and effects discounted at 5%).
Our analysis indicates that there is considerable
agreement on what should be reported, even if the
methodological prescriptions differ slightly from
guideline to guideline. The article by Hjelmgren
et al. [22] includes detail of the methodological
prescriptions.
Relevance of Other Task Force Reports
Four of the other ISPOR Task Forces deal with
aspects of study methodology, namely, those on
modeling, prospective studies, retrospective (data-
base) studies, and quality-of-life. Some of the
reports of these Task Forces make methodological
recommendations, many of which are carried for-
ward as requirements for reporting of results.
Therefore, we refer the reader to the reports of the
relevant Task Forces, particularly in relation to any
requirements for reporting.
Additional Reporting Requirements for 
Decision Makers
Because of the concerns raised by decision makers
about the reliability and relevance of PE/HE stud-
ies, we propose some additional reporting require-
ments below. This represents an ideal list and we
Figure 1  Reporting requirements in 15 published economic evalu-
ation guidelines.
Number of Guidelines Requiring a Report
0 5 10  15
Topic
Objective of study
Target audience 
Viewpoint
Comparator
Discounting 
Uncertainty 
Outcome measurement
Cost/resources measurement
Time horizon 
Modelling 
Aggregated analysis
Form of evaluation 
Incremental analysis
Costs/resources reported separately 
Disaggregated analysis
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recognize that it may not be possible for the authors
of PE/HE studies to address all these points in a
published article. However, serious consideration
should be given to addressing them in formulary
submissions and other direct communications to
decision makers.
Description of relevant patient population(s).
The value for money of a given therapy depends on
the patient population(s) in which it is used. The
size of the patient population also affects budgetary
impact. Therefore, the study report should clearly
identify the relevant patient population(s) and, if
possible, their size in the jurisdiction concerned.
Budgetary perspectives and budget impact.
Decision makers are interested in the cost of adopt-
ing the new therapy on their own budget and other
budgets in their organization. Therefore, the study
report should clearly identify the relevant budgets
and the impact on each of adopting the new
therapy.
Cost-consequences analysis. Decision makers
appreciate a disaggregated presentation of the study
costs and outcomes, prior to any aggregation in an
incremental cost-effectiveness or cost–utility ratio.
Outcomes (consequences) could include changes in
survival, quality of life, or indicators of patient sat-
isfaction. Therefore, the study report should include
disaggregated costs and outcomes, comparing the
new therapy with the existing one (i.e., the most
widely used therapy in the setting concerned).
Costs, consequences, and cost-effectiveness by
patient subgroup. Where there are relevant sub-
groups of the patient populations, decision makers
are interested in how value-for-money varies by
subgroup. Subgroups may be deﬁned by clinical
indication, risk factors, or previous exposure to
treatment. Therefore, where relevant and feasible,
the study report should present costs, consequences
and incremental cost-effectiveness ratio by patient
subgroup.
Practical implications of adopting the new
therapy. Decision makers sometimes ﬁnd it difﬁ-
cult to understand the practical implications of
adopting a therapy with a given incremental cost-
effectiveness ratio. An alternative way of presenting
results would be to explain what the adoption of the
new therapy might mean in terms of budgetary
impact and implications for the health of the rele-
vant patient population(s). The analyst might also
attempt to explain how and when savings in the use
of other health-care resources may be achieved,
although we recognize that much of this is context-
speciﬁc.
Therefore, the study report should attempt to
explain the impact, in practical terms, of adopting
the new therapy.
Listing of key assumptions and data sources.
A key concern of decision makers is transparency in
the reporting of PE/HE studies. At the local level, in
particular, decision makers may not have the time
or expertise to undertake detailed critical appraisals
of studies. Therefore, the study report should list all
the key assumptions and data sources.
Sensitivity analyses using the decision maker’s
own data and assumptions. Economic data do
not easily transfer from place to place, and it is
known that a number of factors are likely to affect
the cost-effectiveness of health-care interventions.
In particular, it would be useful to know which
parameters have the biggest impact on study results.
Therefore, the study report (or model) should facil-
itate sensitivity analyses, using the decision maker’s
own data and assumptions.
The Task Force’s recommendations for addi-
tional reporting requirements are summarized in
Table 2.
Discussion
The Task Force’s recommendations for additional
reporting requirements raise a number of issues.
First, will it be possible to meet these requirements
in all study reports? It is unlikely that the space
restrictions imposed by journals will allow such
detailed reporting in published articles, although it
Table 2 Recommended additional reporting requirements
• The study report should clearly identify the relevant patient 
population(s) and, if possible, their size in the jurisdiction 
concerned.
• The study report should clearly identify the relevant budgets, and 
the impact on each, of adopting the new therapy.
• The study report should include disaggregated costs and 
outcomes, comparing the new therapy with the existing one.
• Where relevant, the study report should present costs, 
consequences, and incremental cost-effectiveness ratio by patient 
subgroup.
• The study report should attempt to explain the impact, in 
practical terms, of adopting the new therapy.
• The study report should list all the key assumptions and data 
sources.
• The study report (or model) should facilitate sensitivity analyses 
using the decision maker’s own data and assumptions.’
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would be useful if authors explored the practical
implications of their ﬁndings to a greater extent
than at present. However, in the main, we expect
that the full implementation of our additional
requirements will be much more feasible in the con-
text of submissions to major payers, such as large
managed care groups or government agencies.
Second, given the burden on manufacturers of
making submissions, is there scope for harmoniza-
tion of decision makers’ requirements? The article
by Hjelmgren et al. [22] and our own review sug-
gests that there are already considerable similarities
between the various ofﬁcial requirements, such that
it is possible for manufacturers to compile a core
economic dossier for a product that can then be
adapted slightly to meet individual requirements.
Over time, as more payers request economic sub-
missions, the pressure from manufacturers for
greater harmonization is likely to increase, but some
adaptation will always be required, given variations
in patient populations, resource availability, and
current clinical practice from one location to
another.
Third, should decision makers at different levels
receive more education in the methodology of PE/
HE studies? The EUROMET survey by Hoffmann
et al. [11] showed that the levels of sophistication
and knowledge among decision makers varied
greatly. Certainly, knowledge is greatest in those set-
tings where there is a formalized procedure for con-
sidering economic data and less throughout the
health-care system more generally. Therefore, in
conjunction with the improvements in study report-
ing recommended here, more attention should be
given to improving decision makers’ understanding
of PE/HE studies.
Fourth, should there be more study of health-care
decision making procedures themselves? In a recent
editorial, Hutton and Brown [23] point out that,
while decision makers often claim that PE/HE stud-
ies are irrelevant or unhelpful, the basis on which
decisions are made is often unclear. If studies of the
relative cost-effectiveness of treatment options are
not relevant, what objectives are decision makers
trying to fulﬁll when they make decisions?
Finally, what additional research could be con-
ducted into decision makers’ needs for PE/HE infor-
mation? One approach would be to undertake new
surveys at the time of methodological advances in
pharmacoeconomics. For example, do decision
makers understand, or indeed prefer, the presenta-
tion of PE/HE results in the form of a cost-
effectiveness acceptability curve [24]? Do they ﬁnd
the results of discrete choice experiments more
informative than those of QALY or willingness-to-
pay estimations [25]?
The other main approach, as opposed to more
surveys, would be to undertake some controlled
experiments, where one group of decision makers
would receive various types of PE/HE information
and the other not. One could then explore the
impact that various types of data have on the out-
come (i.e., decision). While more difﬁcult to under-
take, such research would not be reliant on decision
makers’ survey responses and whether these reﬂect
what they would actually do in practice.
Therefore, while we believe that our recommen-
dations for additional reporting are a useful contri-
bution, there is much more to be done in “bridging
the gap” between the practitioners of PE/HE and
the needs and concerns of those decision makers
they seek to inform.
We are especially grateful to the health-care decision mak-
ers, members of the ISPOR Special Interest Group on
Managed Care/Pharmacy Beneﬁt Management, and other
members of ISPOR that have taken time to give us their
views on PE/HE studies and how the practice of reporting
studies can be improved.
The Task Force is grateful to GlaxoSmithKline for an
unrestricted grant. We are also grateful to François Schu-
bert for his contribution to the work of the Task Force.
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